Raj Bawa is president of Bawa Biotech LLC, a biotech/pharma consultancy and patent law firm based in Ashburn, VA, USA that he founded in 2002. He is an inventor, entrepreneur, professor and registered patent agent licensed to practice before the U.S. Patent & Trademark Office. Trained as a biochemist and microbiologist, he has been an active researcher for over two decades. He has extensive expertise in pharmaceutical sciences, biotechnology, nanomedicine, drug delivery and biodefense, FDA regulatory issues, and patent law. Since 1999, he has held various positions at Rensselaer Polytechnic Institute in Troy, NY, where he is currently an adjunct professor of biological sciences and where he received his doctoral degree in three years (biophysics/biochemistry). Since 2004, he has been an adjunct professor of natural and applied sciences at NVCC in Annandale, VA. He is a scientific advisor to Teva Pharmaceutical Industries, Ltd., Israel. He has served as a principal investigator of National Cancer Institute SBIRs and reviewer for both the NIH and NSF. In the 1990s, Dr. Bawa held various positions at the US Patent & Trademark Office, including primary examiner for 6 years. He is a life member of Sigma Xi, co-chair of the Nanotech Committee of the American Bar Association and serves on the global advisory council of the World Future Society. He is frequently interviewed by the media and appeared in such publications as Nature, MIT Technology Review, American Chemical Socitye CE&N, Business Review, etc. He has authored over 100 publications, co-edited four texts and serves on the editorial boards of 17 peer-reviewed journals, including serving as a Special Associate Editor of Nanomedicine (Elsevier) and an Editor-in-Chief of the Journal of Interdisciplinary Nanomedicine (Wiley). Some of Dr. Bawa’s awards include the Innovations Prize from the Institution of Mechanical Engineers, London, UK (2008); Appreciation Award from the Undersecretary of Commerce, Washington, DC (2001); the Key Award from Rensselaer’s Office of Alumni Relations (2005); and Lifetime Achievement Award from the American Society for Nanomedicine (2014).
He is the principal investigator at the Laboratoty of Immunobiology at Federal University of Rio de Janeiro, Associate Professor at Federal University of Rio de Janeiro, and a Senior Research Specialist from the Presidency of the Oswaldo Cruz Foundation-FIOCRUZ where he investigate the immunological mechanisms associated with changes in central and peripheral lymphoid system in infectious diseases, with major focus in Malaria, Leishmaniasis and Chagas Diseases.
Noah Isakov is a Professor of Immunology in the Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, at Ben Gurion University of the Negev, in Beer Sheva, Israel, where he holds the Joseph H Krupp Chair in Cancer Immunobiology. He obtained his PhD from the Weizmann Institute of Science in Rehovot, Israel (1981) and worked as a postdoctoral researcher at the University of Minnesota in Minneapolis, MN (1981-1983) and the Scripps Research Institute in La Jolla, CA (1983-1987). He performed sabbaticals at the NICHD, National Institutes of Health in Bethesda, MD (1993-1995), the Oklahoma Medical Research Foundation in Oklahoma City, OK (2003-2004), where he held the Esther Greenberg Honors Chair in Biomedical Research, and the Otago University in Dunedin, New Zealand (2015).
Aziz Alami Chentoufi is a Consultant and Head of Immunology/Serology/HLA section at Pathology and Clinical Laboratory Medicine, King Fahad Medical City (KFMC). He is also an Assistant Professor of Immunology at Faculty of Medicine, King Saud Ibn AbdulAziz University. He is the Chairperson of Research Committee of PCLMA-KFMC. He is the Diplomate of the American Board of Medical laboratory Immunology D(ABMLI ), Fellow of the Association of Clinical Sciences (FACSc), accredited by the European Society of Translational Medicine (PCTM) and Fellow of the Academy of translational Medicine (FacadTM). He received his Ph.D. in Biomedical Sciences (Tolerance induction to xenogenic and allogenic antigens using monoclonal antibody anti-igM and anti-IgD) from the University Catholic of Louvain, Brussels, Belgium in 1999. He has done postdoctoral fellowship at McGill University, Montreal, Canada from 1999 to 2004 where he worked on immunogenetic of type 1 Diabetes and gene therapy for graft versus host disease then he was appointed as specialist at the University of California Irvine-Medical Center, Irvine, California, USA in 2006 where he was a key investigator in the development of mucosal vaccine against herpes simplex virus type 1 and 2.
Yaffa Mizrachi Nebenzahl has completed her PhD at The Weizmann Institute, Israel in 1985. She is the Head of the Molecular Microbiology Laboratory in The Shraga Segal Department of Microbiology, Immunology and Genetics at the Faculty of Health Sciences in Ben Gurion University of the Negev, Israel.
? 1996 - Present (Total 21+ years) ? Founder Director Swasthya Santulan Medicare Pvt.Ltd. ? Working as Consulting Acupuncturist ? 2000- Present ? Founder, Director, Head of Management and Teacher, School of Alternative Healing and Acupuncture Insync ( Saheacci), Pune ? 2013-Present ? Authorized Teacher in Acupuncture for Beijing Mebo Training Centre, China for 8 advanced courses in Pulse Diagnosis ? 2016 - Present ? Authorized trainer for NADA ? 2017 ? Lecturer in Acupuncture at University of Perugia, Italy. ? 2017 ? Official Trainer
? March 2017- 1st Indian Woman Acupuncturist to represent India, at United Nations, through (All Shah Behrum Baug Society, Mumbai, recognized as consultative status at UN) for research in Acupuncture in New York in CSW 61, Commission on Status of Women. ? January 2017- First Indian Acupuncturist to introduce the philosophy of Acupuncture at University Of Perugia, Italy. Invited for a key talk on Pulse diagnosis in Acupuncture at Medicine department as well as Nursing department at Perugia and Foligno University, Italy. ? October 2016- First Indian woman Acupuncturist to be invited as a keynote speaker at Chicago, at International Restorative Medicine Conference. ? September 2016- First Indian Woman Acupuncturist to present a research paper at Netherlands in International Traditional Medicine symposium, Amsterdam, Netherlands. ? First Indian woman Acupuncturist to be appointed as an Organising Committee Member, Moderator, and Trainer for 2nd International Restorative Medicine Conference at Vienna, Austria 2017 and Paris 2018. ? 2013- Presented research paper on “Collagen induced arthritis and Acupuncture” at the 6th International conference on Natural Medicine at Paris, France. ? 2003-2017 Researched and presented more than 800 lectures, creating Acupuncture awareness in different social organizations in India and abroad. ? 2005-2014 300+ free treatment camps in rural areas of Maharashtra. ? 2012 Presented Research paper on ‘Convulsions due to cochlear Implantation and Acupuncture healing’ at the 19th International conference of alternative medicine, Kolkata. ? 2010 Presented Research paper on ‘Convulsions due to cochlear Implantation and Acupuncture
M V Raghavendra Rao, PhD, worked as Professor of microbiology, parasitology, immunology and Epidemiology in many universities in India, China, Nepal, Libya, and Philippines. Currently, he is working at Avalon University School of Medicine, Curacao, Netherland Antilles. He has more than 40 years of teaching and research experience. He supervised 3 students for PhD, and 8 students for MPhil. He authored 18 text books. Three universities appointed him as their advisor and 3 universities acknowledged him with fellowships.
Editor-In Chief-Anatomy and Physiology current research (USA) Editor Bio Technology and Microbiology current research International journal (USA)
Graduated in Biological Science (1990), Master in Parasitary Biology by Instituto Oswaldo Cruz-FIOCRUZ (1995), PhD in Sciences by the Institute of Microbiology Prof. Paulo de Góes of the Federal University of Rio de Janeiro (2000), Post-doctorate at the Laboratory of Immunopharmacology of the Department of Physiology and Pharmacodynamics of the Oswaldo Cruz Institute (2000-2002) and in the Program of Cell Biology of the National Jewish Medical and Research Center of Denver, Colorado, USA (2002-2004). He is currently Associate Professor I of the Immunobiology Program of the Biophysics Institute Carlos Chagas Filho of the Federal University of Rio de Janeiro. He has experience in Immunology, with emphasis on Cellular Immunology, Immunoparasitology and Immunomodulation, working mainly in the following subjects: Chagas disease, leishmaniasis, cryptococcosis,
Ahmed Hegazi is currently a Professor of Microbiology and Immunology in the National Research Center, Egypt. Prof. Hegazi received his master’s degree in 1979, and his PhD in 1981. Hegazi's research work has been focused lately on bee products and their therapeutic effects. Hegazi organized and contributed to national and international research projects since 1977 and up till now; he has been the principal investigator on multiple research projects within the National Research Center. He has published 211 scientific papers and articles in national and international journals. He also served on the board of multiple national and international scientific journals. Dr. Hegazi is also the president of the Egyptian Environmental Society for Uses and Production of Bee Products, secretary of the Egyptian Society of Apitherapy, secretary general of the African Federation of Apiculture Associations, and a member of the International Apitherapy Commission (APIMONDIA). Dr. Hegazi awards; First Class Decoration of Excellence, Egypt, 1995, The Senior Scientist Prize of National Research Center, Cairo, Egypt, 1996, The National Scientific Prize In Biological Sciences, Egypt, 1990, The Scientific Prize of The National Research Center, Cairo, Egypt, 1989, The Second Best Research Paper Award, International Congress of Propolis, Bones Aires, Argentina, 2000, Main Speaker Award,10th Academic Conference, PRA and NAS (Nippon Apitherapy Soc.) Japan, 2006, 2 Bronze medals from The International Innovation Fair of the Middle East, Kuwait, 2007 Awarded of Ghazi Wad Allah Salon Prize, 2008, Finally awarded the Merit Ward in Medical Sciences, National Research Centre, Egypt, 2016 and have 4 patents. a
Ljudmila Stojanovich received her Ph.D. in Medicine, with the thesis “Neuropsychiatric manifestations in patients with Systemic Lupus Erythematosus” in 1999. She is the scientific director in the Bezhanijska Kosa, University Medical Center of Belgrade University, where she is currently a Full Research Professor. Dr. Stojanovich’s research focuses on Systemic Lupus Erythematosus, Antiphospholipid Syndrome, and Vaccination in patients with Autoimmune Rheumatic diseases. She is an author of three monographs and of about 250 articles on various aspects of Autoimmune Rheumatic disorders, published in international and domestic journals and in conference proceedings. She is in Editorial Boards (Editorial Boards LUPUS (LONDON). /Reviewer in the “CURRENT CONTENSTS” or “Science citation index”, like LUPUS REWIEWER DATABAS, Cellular and Molecular Neurobiology, The Journal of Vaccine <firstname.lastname@example.org , The Journal of Rheumatology, Allergologia et Immunopathologia and others. She is a member of number International Project, like of “the European Forum on Antiphospholipid Antibodies”, “Multicenter studies antiphospholipid antibodies, infections and autoimmune diseases”. She is a mentor/ Supervisor ships a numbers of post-doc students. She was in Invited Speaker for many lectures in Congresses and Symposia; organizer and Chairman of many Workshops, Seminars and Symposia; the member of the Steering Committee of the “(EULAR) recommendations for vaccination in patients with auto-immune inflammatory rheumatic diseases (AIIRD)”, and EULAR Honorary Member; chairman in the International Congress “Antiphospholipid syndrome (Hughes syndrome) importance of multidisciplinary approaches- 30 years since definition”, 2013, “GRANT 2015” of the EUROPEAN STROKE CONFERENCE » for “excellent research in cerebrovascular diseases reviewed by the Scientific and programmer Committees”, and presented at the 24th Annual Meeting; Vienna, may, 2015. Member of ILLUMINATE steering committee: the phase 3 lupus ILLUMINATES clinical trials of Tabalumab/ Eli Lilly and Company, MD, PhD, FRCP, are willing to serve as a consultant to Lilly Research Laboratories, a division of Eli Lilly and Company (“Lilly”), in connection with the development of Tabalumab also known as LY2439821. Co- Chairman and the lector “LUPUS ACADEMY EASTERN EUROPEAN ROADSHOW of EULAR«: Belgrade, 18TH march 2016, www.lupus-academy.org. Member of the American Association for the Advancement of Science (AAAS) from 2017; The Member of the international team of medical experts for the topic on APS (Hughes Sy). Professor Ljudmila Stojanovich’ Impact Point is 300.14, and number of citattions is 1,998.
Research Interests: · SYSTEMIC LUPUS ERYTHEMATOSUS · ANTIPHOSPHOLIPID SYNDROME · NEUROPSYCHIATRIC MANIFESTATIONS IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASE · VACCINATION IN PATIENTS WITH AUTO-IMMUNE INFLAMMATORY RHEUMATIC DISEASES
Dr Suchkov has been trained at: Lab of Immunology, NEI, Bethesda, MD, USA,, NIH and Lab of Immunology; Wills Eye Hospital, Philadelphia, USA; University of Florida in Gainesville; University of California in S-F (UCSF), USA Center for Autoimmunity Research, Johns Hopkins University, Baltimore, MD, USA as well as at some of the British and Swedish Universities on the invitation of the Royal Society for Immunology and Karolinska Academy, respectively; In 1993-1996, Dr Suchkov was an Executice Secretary-in-Chief of the Editorial Board, Biomedical Science, an international journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK. At present, Dr Sergey Suchkov, M, PhD, is: ? Professor in Immunology, Dept of Pathology, School for Pharmacy, I.M. Sechenov First Moscow State Medical University; ? Dept of Clinical Immunology, School for Clinical Medicine, A.I.Evdokimov Moscow State Medical and Dental University; ? a Dean of the Department (Faculty) of The PPPM Development, and the First Vice-President of the University of World Business, Politics and Law; ? Secretary General, United Cultural Convention (UCC), Cambridge, UK to cover a lot of responsibilities including research in the area of mechanisms of chronization, intertalks between innate and adaptive immunity, and interdisciplinary (medical, bioethical, economical, social and politicxal) issues covering PPPM.
Dr. Hanna is a co-founder of Vaccinogen, Inc., the discoverer and developer of OncoVAX, Vaccinogen’s lead project, and a pioneer in the field of cancer vaccines. He also developed and obtained FDA approval for TICE BCG for treatment of carcinoma in situ ("CIS") bladder cancer which remains the standard of care for prophylaxis of recurrence of superficial bladder cancer and therapy of CIS. Dr. Hanna has not only proven his capabilities as discoverer and developer of clinically beneficial biotherapeutics, but also has raised over $300 million for the final clinical development of OncoVAX. As the director of the National Cancer Institutes, Frederick Cancer Research Center, between 1975 – 1983, he created a center of research excellence and managed over 2,000 technologists consisting of hundreds of MDs and PhDs. A special committee of the National Cancer Advisory Board selected him for the above responsibilities. He previously served as Chairman (Emeritus) and Chief Scientific Officer of Intracel Resources, an integrated biopharmaceutical company that developed cancer vaccines and immunotherapeutic and diagnostic products for both cancers and infectious diseases. Dr. Hanna also served as President and Chief Executive Officer of PerImmune, Inc. before it and Intracel Corp. merged in 1998. From 1985 to 1994, he was the Chief Operating Officer of Organon Teknika Biotechnology Research Institute and Senior Vice President of Organon Teknika Corporation, a subsidiary of Akzo Nobel, N.V., The Netherlands. Prior to that, he was Director of the National Cancer Institute, Frederick Cancer Research Center. Dr. Hanna received a doctoral degree in experimental pathology and immunology from the University of Tennessee. He has over 225 publications to his credit, has 10 patents in immunotherapy and has been the recipient of numerous honors.
Immunology and Immunotherapy.
Giulio Tarro graduated from Medicine School, Naples University (1962). Research Associate, Division of Virology and Cancer Research, Children’s Hospital (1965-1968), Assistant Professor of Research Pediatrics, College Medicine (1968-1969), Cincinnati University, Ohio. Oncological Virology Professor, Naples University (1972-1985). Chief Division Virology (1973-2003), Head Department Diagnostic Laboratories, (2003-2006). D. Cotugno Hospital for Infectious Diseases, Naples; Emeritus, 2006 -. Since 2007 Chairman Committee of Biotechnologies and VirusSphere, World Academy Biomedical Technologies, UNESCO, Adjunct Professor Department Biology, Temple University, College of Science and Technology, Philadelphia, recipient of the Sbarro Health Research Organization lifetime achievement award (2010). His researches have been concerned with the characterization of specific virus-induced tumour antigens, which were the "finger-prints" left behind in human cancer. Achievements include patents in field; discovery of Respiratory Syncytial Virus in infant deaths in Naples and of tumor liberated protein as a tumor associated antigen, 55 kilodalton protein overexpressed in lung tumors and other epithelial adenocarcinomas.
characterization of specific virus-induced tumour antigens, which were the "finger-prints" left behind in human cancer